| Bioactivity | PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC50 of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC50 of 7.5-130 nM. PC-046 induces apoptosis and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice[1]. |
| Target | IC50: 13.4 μM (TrkB); 15.4 μM (IRAK-4); 19.1 μM (Pim-1) |
| CAS | 1202401-59-9 |
| Formula | C22H18N2O3 |
| Molar Mass | 358.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shaw AY, et al., Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer. J Pharmacol Exp Ther. 2009 Nov;331(2):636-47. |
PC-046
CAS: 1202401-59-9 F: C22H18N2O3 W: 358.39
PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC50 of 13.4 μM, 15.4
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.